To show the efficacy of mirabegron for medical expulsive treatment, in patients had intramural located distal ureteral stone. A 80 patients had intramural ureteral stone were assessed retrospectively between April 2017 and January 2018. Mirabegron 50 mg/day + diclofenac 100 mg/day (group 1, n = 40), and only diclofenac 100 mg/day (group 2, n = 40) were administered to patients, consecutively. Age, gender, stone size, laterality, and severity of hydronephrosis were recorded. Spontaneous stone expulsion rates (SER), stone expulsion time, and the number of daily colic episodes were evaluated. In the group 1, one (2.5%) patient was excluded due to nasopharyngitis, and one (2.5%) patient was excluded due to 5 mmHg systolic blood pressure increase. In addition, four (10%) patients in group 1, and six (15%) patients in group 2, who did not attend follow-up examinations, were excluded from the study. There was not any statistically significant difference between the two groups in terms of age, gender, stone location, severity of hydronephrosis, stone size (p = 0.736, p = 0.310, p = 0.467, p = 0.801, p = 0.761, consecutively). Spontaneous expulsion ratios were calculated as 73.52% in group 1, and 47.05% in group 2 (p = 0.026). However, there was not any statistically significant difference in terms of stone expulsion time (p = 0.979). SER for patients had ≤ 6 mm stones was higher in group 1 (87.5 vs 52.49%, p = 0.031). In addition, group 2 patients had more pain episodes (1.02 ± 0.52 vs. 1.29 ± 0.57, p = 0.049). In the current study, mirabegron has been shown to be an efficient, safe and a new treatment modality, with lower side effect profile for the intramural located distal ureteral stones.

The QLB III was observed to be effective in pain control and reducing morphine consumption during the postoperative 48 hours follow-up after PCNL.

A subset of renal cell carcinoma (RCC) patients has been shown to respond to anti-EGFR therapy. As KRAS and BRAF mutations are associated with poor response to anti-EGFR therapy in some cancers, it has been suggested that screening for KRAS and BRAF mutations in RCC may be a promising strategy to identify patients who might respond to EGFR-targeted therapy. The aim of this study was to investigate the mutation status of EGFR, KRAS and BRAF in RCC patients. Renal tumors and normal renal samples from forty-eight patients who underwent radical or partial nephrectomy for kidney cancer were used in this study. Histological classification of the tumors was performed according to International Union against Cancer (UICC) / American Joint Committee on Cancer (AJCC) classification. Seventeen patients (48%) had clear-cell RCC, 7 (20%) had chromophobe RCC, and 11 patients (32%) had papillary RCC. DNA isolated from the samples was subjected to melting curve mutation analysis for EGFR, BRAF and KRAS using ABI-3130 DNA sequencer. DNA sequencing analysis of RCC samples, when compared with morphologically normal matched regions, did not show any exon mutations. Our results do not support the notion that EGFR, KRAS and BRAF might be mutated in RCC.

No abstract

What's known on the subject? and What does the study add? Amaç: Bu çalışmanın amacı, lokalize prostat kanseri nedeniyle radikal prostatektomi yapılan hastalarda preoperatif trombosit kitle indeksi (PMI) ile tümörün patolojik özellikleri ve postoperatif biyokimyasal nüks arasındaki ilişkiyi araştırmaktır. Gereç ve Yöntem: Nisan 2004 ile Nisan 2017 arasında lokalize prostat kanseri nedeniyle radikal prostatektomi yapılan 141 hastanın verileri retrospektif olarak tarandı. Hastaların yaş, preoperatif prostat spesifik antijen (PSA), trombosit sayısı, ortalama trombosit hacmi ve PMI değerleri, N/L oranı, tümör evresi, Gleason skoru, tümör hacmi, lenf nodu tutulumu, cerrahi sınır pozitifliği ve 3. ayda biyokimyasal nüks olup olmadığı kaydedildi. Ameliyat öncesi PMI değerinin yaş, PSA, patolojik parametreler, cerrahi sınır pozitifliği ve biyokimyasal nüks ile olan ilişkisi incelendi. Bulgular: Hastaların yaş ortalaması 61,79±5,98 yıl, ortalama PSA değeri 9,50±6,69 ng/mL, ortalama PMI değeri 2003,91±486,69 ve ortalama N/L oranı 2,79±2,06 idi. PMI değeri ile PSA, patolojik evre, Gleason skoru, lenf nodu tutulumu, tümör hacmi, cerrahi sınır pozitifliği, biyokimyasal nüks arasında bir korelasyon izlenmedi. PMI ile Gleason skoru arasında istatistiksel olarak anlamlı negatif korelasyon izlendi. Sonuç: Çalışmamızda prostat kanseri nedeniyle radikal prostatektomi uygulanmış hastalarda ameliyat öncesi PMI değerini, erken biyokimyasal nüks için prognostik bir faktör olarak gösteremedik. Genelleme yapabileceğimiz daha iyi bir sonuç elde etmek için, daha geniş hasta serileri ile prospektif olarak tasarlanmış çalışmalara ihtiyaç vardır.